AuRx, Inc. is a privately held company based in Glen Burnie, Maryland, specializing in the development of innovative medical solutions. With a recent tentative approval from the Mexican Ministry of Health, AuRx is set to conduct Phase 3 trials for their groundbreaking product, Theraherp. Theraherp, also known as ICP10 PK, is a recombinant that effectively suppresses lesions and other symptoms in individuals infected with genital herpes, surpassing the efficacy of currently available drugs.
Building on the success of their initial Phase I/II clinical trial in Mexico City, where Theraherp demonstrated exceptional tolerability and eliminated recurrences of lesions in 84% of vaccinated patients for a full year, AuRx anticipates that the Phase III trial will yield comparable results. This trial, a placebo-controlled, double-blinded multi-center study with a 6-month follow-up, aims to confirm the efficacy of Theraherp and pave the way for its approval and subsequent availability in Mexico.
Generated from the website